AUTHOR INDEX

Volume 85 • 2001

Abe, N. *See* Kitano, S.
Aizawa, Y. *See* Ozaki, K.
Akaike, N. *See* Munakata, M.
Amano, T. *See* Teranishi, Y.
Arai, K. *See* Honda, H.
Araki, H. *See* Munakata, M.
Arens, T. *See* Qadri, F.
Atsuki, K. *See* Ohi, Y.

Baba, A. *See* Kitano, S.
Baba, J. *See* Fujishiro, J.
Baba, K. *See* Guo, L.-Q.
Bilge, S.S. *See* Kurt, M.
Bittinger, F. *See* Kirkpatrick, C.J.
—— *See* Wessler, I.

Celik, S. *See* Kurt, M.
Chang, Y.-Y. *See* Huang, Y.-T.
Chaudhuri, L. *See* Maity, S.
Chen, C.-F. *See* Shi, C.-C.
Chen, Q.-Y. *See* Guo, L.-Q.
Cheng, H.W. *See* Hu, C.M.
Cheng, Y.W. *See* Hu, C.M.
Choi, K.C. *See* Lee, J.U.

Daniel, E.E. *See* Kwan, C.-Y.
Dendorfer, A. *See* Wethmar, U.
Dohmoto, H. *See* Takahara, A.
Dominiak, P. *See* Qadri, F.
—— *See* Wethmar, U.
Duspara, P.A. *See* Kwan, C.-Y.
Dutta, P., Ryan, D.E. and Tabrizchi, R.
Rolipram on hemodynamics in LPS-treated rats 241

Egashira, T. *See* Takayama, F.
Elwan, M.A. *See* Sakuragawa, N.
Endoh, T., Tajima, A., Izumimoto, N., Suzuki, Tomohiko, Saitoh, A., Suzuki, Tsutomu, Narita, M., Kamei, J., Tseng, L.F., Mizoguchi, H. and Nagase, H.
Antinociception of TRK-820 in monkeys 282

Fujii, H. *See* Honda, H.
Fujii, T. *See* Sakuragawa, N.
Fujii, T. and Kawashima, K.
Lymphatic non-neuronal acetylcholine 11
Fujimura, A. *See* Sugimoto, K.
Fujishiro, J., Imanishi, T., Baba, J. and Kosaka, K.
Antidepressant effect in tail suspension test 327
Fujita, T., Meguro, T., Izumo, N., Yasutomi, C., Fukuyama, R., Nakamuta, H. and Koida, M.
Phosphate accelerates ATDC5 mineralization 278
Fukuyama, R. *See* Fujita, T.
Funakami, Y. *See* Hata, T.

Ganguly, D.K. *See* Maity, S.
Gemba, M. *See* Kohda, Y.
Gomora, J.C. *See* Heady, T.N.
Guo, L.-Q., Taniguchi, M., Chen, Q.-Y., Baba, K. and Yamazoe, Y.
Herbal medicines inhibit CYP3A 399

Harrison, P.H.M. *See* Kwan, C.-Y.
Hashimoto, K. *See* Takahara, A.
Hata, T., Itoh, E., Funakami, Y., Ishida, K. and Uchida, Shuji
Stress-induced hypotension and AF-DX 116 313
Hata, T., Nishikawa, H., Itoh, E. and Funakami, Y.
Stress and anxiety 189
Hatano, Y. *See* Kinoshita, H.
Häuser, W. *See* Qadri, F.
Heady, T.N., Gomora, J.C., Macdonald, T.L. and Perez-Reyes, E.
Pharmacology of T-type channels 339
Hibi, S. *See* Hida, T.
Hida, M. *See* Sakuma, T.
Hida, T., Tai, K., Tokuhara, N., Ishibashi, A., Kikuchi, K., Hibi, S., Yoshimura, H., Nagai, M., Yamauchi, T. and Kobayashi, Seiichi
RXR pathway in cellular function 60
Honda, H., Moroe, H., Fujii, H., Arai, K., Notoya, Y. and Kogo, H.
Short term hypercholesterolemia and EDHF 203
Hong, C.-Y. *See* Huang, Y.-T.
Hori, M. *See* Miyamoto, S.
Hori, Y., Hoshino, J., Yamazaki, C., Sekiguchi, T., Miyauchi, S. and Horie, K.
Effects of CS in a colitis model 155
Horie, K. *See* Hori, Y.
Horikawa, N., Kuribayashi, Y., Itoh, N., Nishioka, M., Matsui, K., Kawamura, N. and Ohashi, N.
Na^+/H^+ exchange and endothelial dysfunction 271
Horikoshi, K. *See* Miyake, K.
Horikoshi, K., Yokoyama, T., Kishibayashi, N., Ohmori, K., Ishii, A. and Karasawa, A.
Involvement of 5-HT_4 receptors in emesis 70
Horinouchi, T. and Koike, K.
Effects of (±)-pindolol at atypical β-AR 35
Horiuchi, K. *See* Matsui, Y.
Hoshino, J. *See* Hori, Y.
Hu, C.M., Cheng, H.W., Cheng, Y.W. and Kang, J.J.
Vasorelaxation induced by sanguinarine 47
Huang, Y.-T., Lin, H.-C., Chang, Y.-Y., Yang, Y.-Y., Lee, S.-D. and Hong, C.-Y.
Synephrine ameliorates portal hypertension 183

Iida, N. *See* Teranishi, Y.
Ikeda, M. *See* Tabuchi, M.
Ikeda, Y. *See* Miyake, K.
Imaizumi, Y. *See* Ohi, Y.
Imanishi, T. *See* Fujishiro, J.
Imura, Y. *See* Noda, M.
Inagaki, C. *See* Mishima, K.
Inagaki, N. *See* Kawada, N.
Inoue, M. *See* Sakuma, T.
Iranami, H. *See* Kinoshita, H.
Irimura, K. *See* Kitano, S.
Ishibashi, A. *See* Hida, T.
Ishibashi, T. *See* Ozaki, K.
Ishida, K. *See* Hata, T.
Ishii, A. *See* Horikoshi, K.
—— *See* Miyake, K.
Ishii, T. *See* Satoh, E.
Ishioka, N. *See* Teranishi, Y.
Ito, T. *See* Tabuchi, M.
Itoh, E. *See* Hata, T.

AUTHOR INDEX

Volume 85 • 2001

Abe, N. *See* Kitano, S.
Aizawa, Y. *See* Ozaki, K.
Akaike, N. *See* Munakata, M.
Amano, T. *See* Teranishi, Y.
Arai, K. *See* Honda, H.
Araki, H. *See* Munakata, M.
Arens, T. *See* Qadri, F.
Atsuki, K. *See* Ohi, Y.

Baba, A. *See* Kitano, S.
Baba, J. *See* Fujishiro, J.
Baba, K. *See* Guo, L.-Q.
Bilge, S.S. *See* Kurt, M.
Bittinger, F. *See* Kirkpatrick, C.J.
—— *See* Wessler, I.

Celik, S. *See* Kurt, M.
Chang, Y.-Y. *See* Huang, Y.-T.
Chaudhuri, L. *See* Maity, S.
Chen, C.-F. *See* Shi, C.-C.
Chen, Q.-Y. *See* Guo, L.-Q.
Cheng, H.W. *See* Hu, C.M.
Cheng, Y.W. *See* Hu, C.M.
Choi, K.C. *See* Lee, J.U.

Daniel, E.E. *See* Kwan, C.-Y.
Dendorfer, A. *See* Wethmar, U.
Dohmoto, H. *See* Takahara, A.
Dominiak, P. *See* Qadri, F.
—— *See* Wethmar, U.
Duspara, P.A. *See* Kwan, C.-Y.
Dutta, P., Ryan, D.E. and Tabrizchi, R.
Rolipram on hemodynamics in LPS-treated rats 241

Egashira, T. *See* Takayama, F.
Elwan, M.A. *See* Sakuragawa, N.
Endoh, T., Tajima, A., Izumimoto, N., Suzuki, Tomohiko, Saitoh, A., Suzuki, Tsutomu, Narita, M., Kamei, J., Tseng, L.F., Mizoguchi, H. and Nagase, H.
Antinociception of TRK-820 in monkeys 282

Fujii, H. *See* Honda, H.
Fujii, T. *See* Sakuragawa, N.
Fujii, T. and Kawashima, K.
Lymphatic non-neuronal acetylcholine 11
Fujimura, A. *See* Sugimoto, K.
Fujishiro, J., Imanishi, T., Baba, J. and Kosaka, K.
Antidepressant effect in tail suspension test 327
Fujita, T., Meguro, T., Izumo, N., Yasutomi, C., Fukuyama, R., Nakamuta, H. and Koida, M.
Phosphate accelerates ATDC5 mineralization 278
Fukuyama, R. *See* Fujita, T.
Funakami, Y. *See* Hata, T.

Ganguly, D.K. *See* Maity, S.
Gemba, M. *See* Kohda, Y.
Gomora, J.C. *See* Heady, T.N.
Guo, L.-Q., Taniguchi, M., Chen, Q.-Y., Baba, K. and Yamazoe, Y.
Herbal medicines inhibit CYP3A 399

Harrison, P.H.M. *See* Kwan, C.-Y.
Hashimoto, K. *See* Takahara, A.
Hata, T., Itoh, E., Funakami, Y., Ishida, K. and Uchida, Shuji
Stress-induced hypotension and AF-DX 116 313
Hata, T., Nishikawa, H., Itoh, E. and Funakami, Y.
Stress and anxiety 189
Hatano, Y. *See* Kinoshita, H.
Häuser, W. *See* Qadri, F.
Heady, T.N., Gomora, J.C., Macdonald, T.L. and Perez-Reyes, E.
Pharmacology of T-type channels 339
Hibi, S. *See* Hida, T.
Hida, M. *See* Sakuma, T.
Hida, T., Tai, K., Tokuhara, N., Ishibashi, A., Kikuchi, K., Hibi, S., Yoshimura, H., Nagai, M., Yamauchi, T. and Kobayashi, Seiichi
RXR pathway in cellular function 60
Honda, H., Moroe, H., Fujii, H., Arai, K., Notoya, Y. and Kogo, H.
Short term hypercholesterolemia and EDHF 203
Hong, C.-Y. *See* Huang, Y.-T.
Hori, M. *See* Miyamoto, S.
Hori, Y., Hoshino, J., Yamazaki, C., Sekiguchi, T., Miyauchi, S. and Horie, K.
Effects of CS in a colitis model 155
Horie, K. *See* Hori, Y.
Horikawa, N., Kuribayashi, Y., Itoh, N., Nishioka, M., Matsui, K., Kawamura, N. and Ohashi, N.
Na^+/H^+ exchange and endothelial dysfunction 271
Horikoshi, K. *See* Miyake, K.
Horikoshi, K., Yokoyama, T., Kishibayashi, N., Ohmori, K., Ishii, A. and Karasawa, A.
Involvement of 5-HT_4 receptors in emesis 70
Horinouchi, T. and Koike, K.
Effects of (±)-pindolol at atypical β-AR 35
Horiuchi, K. *See* Matsui, Y.
Hoshino, J. *See* Hori, Y.
Hu, C.M., Cheng, H.W., Cheng, Y.W. and Kang, J.J.
Vasorelaxation induced by sanguinarine 47
Huang, Y.-T., Lin, H.-C., Chang, Y.-Y., Yang, Y.-Y., Lee, S.-D. and Hong, C.-Y.
Synephrine ameliorates portal hypertension 183

Iida, N. *See* Teranishi, Y.
Ikeda, M. *See* Tabuchi, M.
Ikeda, Y. *See* Miyake, K.
Imaizumi, Y. *See* Ohi, Y.
Imanishi, T. *See* Fujishiro, J.
Imura, Y. *See* Noda, M.
Inagaki, C. *See* Mishima, K.
Inagaki, N. *See* Kawada, N.
Inoue, M. *See* Sakuma, T.
Iranami, H. *See* Kinoshita, H.
Irimura, K. *See* Kitano, S.
Ishibashi, A. *See* Hida, T.
Ishibashi, T. *See* Ozaki, K.
Ishida, K. *See* Hata, T.
Ishii, A. *See* Horikoshi, K.
—— *See* Miyake, K.
Ishii, T. *See* Satoh, E.
Ishioka, N. *See* Teranishi, Y.
Ito, T. *See* Tabuchi, M.
Itoh, E. *See* Hata, T.

Itoh, N. *See* Horikawa, N.
Izumi, M. *See* Miyamoto, S.
Izumi, S. *See* Sakai, I.
Izumimoto, N. *See* Endoh, T.
Izumo, N. *See* Fujita, T.

Kakihana, M. *See* Kitanaka, J.
Kakutani, T. *See* Kinoshita, H.
Kamei, J. *See* Endoh, T.
—— *See* Onodera, K.
Kanai, K. *See* Matsui, Y.
Kang, D.G. *See* Lee, J.U.
Kang, J.J. *See* Hu, C.M.
Kang, T.M., Kim, Y.C., Sim, J.H., Rhee, J.C., Kim, S.J., Uhm, D.Y., So, I. and Kim, K.W.
NSC_{CCh} in guinea pig gastric myocytes 291
Karaki, H. *See* Miyamoto, S.
Karasawa, A. *See* Horikoshi, K.
—— *See* Miyake, K.
Katunuma, N. *See* Kitano, S.
Kawada, N., Tanaka, Hiroyuki, Takizawa, T., Yamada, T., Takahashi, Y., Masuda, T., Inagaki, N. and Nagai, H.
Airway responsiveness and mast cells 250
Kawamura, M., Niitsu, A., Nishi, H. and Masaki, E.
ATP and ACTH-induced steroidogenesis 376
Kawamura, N. *See* Horikawa, N.
Kawasaki, H. *See* Mishima, K.
Kawashima, K. *See* Fujii, T.
—— *See* Sakuragawa, N.
Kawashima, K. and Nomura, Y.
Non-neuronal cholinergic system 1
Kesim, Y. *See* Kurt, M.
Kikuchi, K. *See* Hida, T.
Kilbinger, H. *See* Kirkpatrick, C.J.
—— *See* Wessler, I.
Kim, K.W. *See* Kang, T.M.
Kim, S.J. *See* Kang, T.M.
Kim, S.W. *See* Lee, J.U.
Kim, Y.C. *See* Kang, T.M.
Kimura, J. *See* Watanabe, Yasuhide
Kinoshita, H., Kakutani, T., Iranami, H. and Hatano, Y.
Levcromakalim and hypertension 29
Kirkpatrick, C.J. *See* Wessler, I.
Kirkpatrick, C.J., Bittinger, F., Unger, R.E., Kriegsmann, J., Kilbinger, H. and Wessler, I.
Endothelial non-neuronal acetylcholine 24
Kishibayashi, N. *See* Horikoshi, K.
Kitamura, K. *See* Uchida, R.
Kitamura, K. and Yamazaki, J.
Role of Cl^- conductance in vascular tone 351
Kitanaka, J., Kitanaka, N., Tsujimura, T., Kakihana, M., Terada, N. and Takemura, M.
HMT mRNA localization in jejunum 105
Kitanaka, N. *See* Kitanaka, J.
Kitano, S., Irimura, K., Sasaki, T., Abe, N., Baba, A., Miyake, Y., Katunuma, N. and Yamamoto, K.
Effect of leupeptin on gingivitis 84
Ko, K.-M., Mak, D.H.F., Poon, M.K.T. and Yiu, H.-Y.
Altered I-R injury in diabetic hearts 435
Kobayashi, Seiichi *See* Hida, T.
Kobayashi, Shinichi *See* Shimizu, H.
Kobayashi, T. *See* Okamoto, T.
Kogo, H. *See* Honda, H.
Kohda, Y. and Gemba, M.
cAMP and PMA on CER-induced renal injury 54
Kohno, S. *See* Nabe, T.
Koida, M. *See* Fujita, T.
Koike, K. *See* Horinouchi, T.
Kosaka, K. *See* Fujishiro, J.
Koseki, J. *See* Nagamatsu, T.
Kriegsmann, J. *See* Kirkpatrick, C.J.
Kubota, Y. *See* Shinozuka, K.
Kukula, O. *See* Kurt, M.
Kumai, T. *See* Shimizu, H.
Kunitomo, M. *See* Shinozuka, K.
Kuribayashi, Y. *See* Horikawa, N.
Kurt, M., Bilge, S.S., Kukula, O., Kesim, Y. and Celik, S.
NO and lidocaine-induced convulsion 92
Kwan, C.-Y., Harrison, P.H.M., Duspara, P.A. and Daniel, E.E.
Vascular effects of pramanicin 234
Kwon, Y.M. *See* Shinozuka, K.

Lee, J.U., Yoo, K.S., Kang, D.G., Kim, S.W. and Choi, K.C.
Gentamicin decreases AQP2 water channels 391
Lee, S.-D. *See* Huang, Y.-T.
Liao, J.-F. *See* Shi, C.-C.
Lin, H.-C. *See* Huang, Y.-T.

Macdonald, T.L. *See* Heady, T.N.
Maity, S., Vedasiromoni, J.R., Chaudhuri, L. and Ganguly, D.K.
Black tea and motility changes by ulcerogens 358
Mak, D.H.F. *See* Ko, K.-M.
Makino, T. *See* Sakai, I.
Masaki, E. *See* Kawamura, M.
Masuda, T. *See* Kawada, N.
Matsubara, T. *See* Ozaki, K.
Matsuda, A. *See* Shuto, S.
Matsueda, K. *See* Uchida, Masayuki
Matsui, K. *See* Horikawa, N.
Matsui, Y., Horiuchi, K., Yamamoto, K. and Kanai, K.
Pharmacological properties of R-755 423
Matsuo, T. *See* Noda, M.
Meguro, T. *See* Fujita, T.
Mishima, K., Otani, H., Tanabe, T., Kawasaki, H., Oshiro, A., Saito, N., Ogawa, R. and Inagaki, C.
α_2-Adrenoceptor and synoviocyte population 214
Miyake, K., Horikoshi, K., Ikeda, Y., Ishii, A. and Karasawa, A.
Olopatadine and mediator release in nose 453
Miyake, Y. *See* Kitano, S.
Miyamoto, S., Hori, M., Izumi, M., Ozaki, H. and Karaki, H.
Isoproterenol-induced Ca^{2+}-desensitization 75
Miyauchi, S. *See* Hori, Y.
Mizoguchi, H. *See* Endoh, T.
Mizutani, N. *See* Nabe, T.
Moroe, H. *See* Honda, H.
Munakata, M., Noguchi, K., Araki, H. and Akaike, N.
Activation of K^+ current by VA-045 124
Murano, T. *See* Sakai, I.
Muraoka, A. *See* Uchida, Masayuki

Nabe, T., Mizutani, N., Osaki, S., Sugahara, S., Takenaka, H. and Kohno, S.
Guinea pig models of allergic rhinitis 409
Nagai, H. *See* Kawada, N.
Nagai, M. *See* Hida, T.
Nagamatsu, T., Nagao, T., Koseki, J., Sugiura, M., Nishiyama, T. and Suzuki, Y.
Clearance of aggregated protein in glomeruli 139
Nagano-Tsuge, H. *See* Noda, M.
Nagao, T. *See* Nagamatsu, T.
Nagase, H. *See* Endoh, T.
Naka, T. *See* Noda, M.

Nakagawa, H. *See* Suzuki-Nishimura, Tamiko
Nakamura, K. *See* Shinozuka, K.
Nakamuta, H. *See* Fujita, T.
Nambu, Y. *See* Sakuma, T.
Narita, M. *See* Endoh, T.
Niitsu, A. *See* Kawamura, M.
Nishi, H. *See* Kawamura, M.
Nishikawa, H. *See* Hata, T.
Nishimura, M. *See* Satoh, E.
Nishio, M. *See* Ozaki, K.
Nishioka, M. *See* Horikawa, N.
Nishiyama, T. *See* Nagamatsu, T.
Noda, M., Matsuo, T., Nagano-Tsuge, H., Ohta, M., Sekiguchi, M., Shibouta, Y., Naka, T. and Imura, Y.
Ang II and NIDDM nephropathy in rats 416
Noguchi, K. *See* Munakata, M.
Nomura, Y. *See* Kawashima, K.
—— *See* Okuma, Y.
Notoya, Y. *See* Honda, H.

Ochi, T., Yamane-Sugiyama, A., Ohkubo, Y., Sakane, K. and Tanaka, Hirokazu
Anti-inflammatory effect of FR188582 175
Ogawa, R. *See* Mishima, K.
Ohashi, N. *See* Horikawa, N.
Ohi, Y., Atsuki, K., Torii, Y., Ohizumi, Y., Watanabe, M. and Imaizumi, Y.
Ca^{2+} release in smooth muscle cells 382
Ohizumi, Y. *See* Ohi, Y.
Ohkubo, Y. *See* Ochi, T.
Ohmori, K. *See* Horikoshi, K.
—— *See* Tamura, T.
Ohta, M. *See* Noda, M.
Ohya, N. *See* Sakuma, T.
Okabe, S. *See* Okamoto, T.
Okamoto, T., Yoshida, S., Kobayashi, T. and Okabe, S.
Coumarins inhibit hepatitis 95
Okuma, Y. and Nomura, Y.
ACh and IL-2 synthesis in lymphocytes 16
Okuwaki, S. *See* Sakai, I.
Onodera, K., Zushida, K. and Kamei, J.
Antinociceptive effect of vitamin K_2 335
Osaki, S. *See* Nabe, T.
Osanai, K. *See* Sakuma, T.
Oshiro, A. *See* Mishima, K.
Otani, H. *See* Mishima, K.
Ozaki, H. *See* Miyamoto, S.
Ozaki, K., Yamamoto, T., Ishibashi, T., Matsubara, T., Nishio, M. and Aizawa, Y.
Fluvastatin regulates eNOS and ET-1 147
Ozeki, S. *See* Uchida, R.

Perez-Reyes, E. *See* Heady, T.N.
Poon, M.K.T. *See* Ko, K.-M.

Qadri, F., Arens, T., Schwartz, E.C., Häuser, W. and Dominiak, P.
Adrenal NOS activity/expression in SHR 365

Raasch, W. *See* Wethmar, U.
Rhee, J.C. *See* Kang, T.M.
Ryan, D.E. *See* Dutta, P.

Saito, N. *See* Mishima, K.
Saitoh, A. *See* Endoh, T.
Sakai, I., Izumi, S., Murano, T., Okuwaki, S., Makino, T. and Suzuki, Takashi
Aldose reductase inhibitor in tea 322
Sakane, K. *See* Ochi, T.
Sakuma, T., Hida, M., Nambu, Y., Osanai, K., Toga, H., Takahashi, K., Ohya, N., Inoue, M. and Watanabe, Yoh
Denopamine effect in hyperoxic rat lungs 161
Sakuragawa, N., Elwan, M.A., Uchida, Saiko, Fujii, T. and Kawashima, K.
Non-neuronal function of amniotic epithelial cells 20
Sasaki, T. *See* Kitano, S.
Satoh, E., Ishii, T. and Nishimura, M.
MTX-induced increase in $[Ca^{2+}]_i$ 98
Schwartz, E.C. *See* Qadri, F.
Sekiguchi, M. *See* Noda, M.
Sekiguchi, T. *See* Hori, Y.
Shi, C.-C., Liao, J.-F. and Chen, C.-F.
Vasorelaxation of harmala alkaloids 299
Shibouta, Y. *See* Noda, M.
Shimizu, H., Kumai, T. and Kobayashi, Shinichi
TH and cyclosporine-induced hypertension 306
Shinozuka, K., Tanioka, Y., Kwon, Y.M., Tanaka, N., Kubota, Y., Nakamura, K. and Kunitomo, M.
Prejunctional ATP receptor in rat artery 41
Shoda, R. *See* Uchida, Masayuki
Shuto, S., Yoshii, K. and Matsuda, A.
PPDC, a novel NMDA-receptor antagonist 207
Sim, J.H. *See* Kang, T.M.
So, I. *See* Kang, T.M.
Sugahara, S. *See* Nabe, T.
Sugimoto, K., Tsuruoka, S. and Fujimura, A.
NO synthesis inhibition and fibrinogen 114
Sugino, H. *See* Teranishi, Y.
Sugiura, M. *See* Nagamatsu, T.
Sugiyama, A. *See* Takahara, A.
Suzuki, M. *See* Tabuchi, M.
Suzuki, Takashi *See* Sakai, I.
Suzuki, Tomohiko *See* Endoh, T.
Suzuki, Tsutomu *See* Endoh, T.
Suzuki, Y. *See* Nagamatsu, T.
Suzuki-Nishimura, Tamiko, Nakagawa, H. and Uchida, Masaatsu K.
SUL-1 inhibited the activation by DSA 443

Tabrizchi, R. *See* Dutta, P.
Tabuchi, M., Umegaki, K., Ito, T., Suzuki, M., Ikeda, M. and Tomita, T.
Disturbed circadian rhythm at stroke-onset 197
Tabuchi, Y.
Characterization and application of GSM06 117
Tai, K. *See* Hida, T.
Tajima, A. *See* Endoh, T.
Takahara, A., Dohmoto, H., Yoshimoto, R., Sugiyama, A. and Hashimoto, K.
Cardiovascular action of AH-1058 331
Takahashi, K. *See* Sakuma, T.
Takahashi, Y. *See* Kawada, N.
Takayama, F., Egashira, T. and Yamanaka, Y.
Ninjin-yoei-to effect on oxidative damage 227
Takemura, M. *See* Kitanaka, J.
Takenaka, H. *See* Nabe, T.
Takizawa, T. *See* Kawada, N.
Tamura, T. and Ohmori, K.
Diacerein and proteoglycan degradation 101
Tanabe, T. *See* Mishima, K.
Tanaka, Hirokazu *See* Ochi, T.
Tanaka, Hiroyuki *See* Kawada, N.
Tanaka, N. *See* Shinozuka, K.
Taniguchi, M. *See* Guo, L.-Q.

Tanioka, Y. *See* Shinozuka, K.
Terada, N. *See* Kitanaka, J.
Teranishi, Y., Iida, N., Ishioka, N., Sugino, H. and Amano, T.
Hindquarter compensator of SHRs 109
Toga, H. *See* Sakuma, T.
Tokuhara, N. *See* Hida, T.
Tomita, T. *See* Tabuchi, M.
Torii, Y. *See* Ohi, Y.
Tseng, L.F. *See* Endoh, T.
Tsujimura, T. *See* Kitanaka, J.
Tsuruoka, S. *See* Sugimoto, K.

Uchida, Masaatsu K. *See* Suzuki-Nishimura, Tamiko
Uchida, Masayuki, Matsueda, K., Shoda, R., Muraoka, A. and Yamato, S.
NO inhibits gastric erosions through PG 133
Uchida, R., Yamazaki, J., Ozeki, S. and Kitamura, K.
Open-channel blockade by cilnidipine 260
Uchida, Saiko *See* Sakuragawa, N.
Uchida, Shuji *See* Hata, T.
Uhm, D.Y. *See* Kang, T.M.
Umegaki, K. *See* Tabuchi, M.
Unger, R.E. *See* Kirkpatrick, C.J.

Vedasiromoni, J.R. *See* Maity, S.

Watanabe, M. *See* Ohi, Y.
Watanabe, Yasuhide and Kimura, J.
Bepridil blocks cardiac I_{NCX} 370
Watanabe, Yoh *See* Sakuma, T.
Wessler, I. *See* Kirkpatrick, C.J.
Wessler, I., Kilbinger, H., Bittinger, F. and Kirkpatrick, C.J.
Non-neuronal acetylcholine 2
Wethmar, U., Raasch, W., Dendorfer, A. and Dominiak, P.
Interaction between AT- and I-receptors 167

Yamada, T. *See* Kawada, N.
Yamamoto, K. *See* Kitano, S.
—— *See* Matsui, Y.
Yamamoto, T. *See* Ozaki, K.
Yamanaka, Y. *See* Takayama, F.
Yamane-Sugiyama, A. *See* Ochi, T.
Yamato, S. *See* Uchida, Masayuki
Yamauchi, T. *See* Hida, T.
Yamazaki, C. *See* Hori, Y.
Yamazaki, J. *See* Kitamura, K.
—— *See* Uchida, R.
Yamazoe, Y. *See* Guo, L.-Q.
Yang, Y.-Y. *See* Huang, Y.-T.
Yasutomi, C. *See* Fujita, T.
Yiu, H.-Y. *See* Ko, K.-M.
Yokoyama, T. *See* Horikoshi, K.
Yoo, K.S. *See* Lee, J.U.
Yoshida, S. *See* Okamoto, T.
Yoshii, K. *See* Shuto, S.
Yoshimoto, R. *See* Takahara, A.
Yoshimura, H. *See* Hida, T.

Zushida, K. *See* Onodera, K.

SUBJECT INDEX

Volume 85 • 2001

Acetylcholine 11, 20
Acetylcholine, cytomolecule 2
Acyl-CoA:cholesterol acyltransferase (ACAT) 423
ACAT inhibition 423
Adenosine 41
Adjuvant arthritis 175
Adrenal cortex 376
Adrenal gland 365
α_1-Adrenoceptor stimulation 241
α_2-Adrenoceptor stimulation 214
β-Adrenoceptor, atypical 35
β_3-Adrenoceptor 35
Adrenocorticotropic hormone 376
AF-DX 116 313
Agglutinin, *Datura stramonium* 443
Aggregated protein 139
AH-1058 (4-(5*H*-dibenzo[*a,d*]cyclohepten-5-ylidene)-1-[(*E*)-3-(3-methoxy-2-nitro)phenyl-2-propenyl]piperidine hydrochloride) 331
Airway inflammation 250
Aldose reductase 322
Alimentary tract disease 155
Allergic rhinitis 409
Alveolar epithelium 161
Amiloride 339
Amniotic epithelial cell (human and monkey) 20
Anesthetic 339
Angiotensin-converting enzyme inhibitor 365
Angiotensin II-receptor 167
Angiotensin II-receptor antagonist 416
Antiarrhythmic drug 370
Antidepressant 327
Antiepileptic 339
Antifungal agent 234
Antihypertensive 339
Anti-inflammation 155
Antinociception 335
Antinociceptive effect 282
Antipsychotic 339
Anxiety 189
Aorta 47
Aquaporin channel 391
Arg-gingipain 84
L-Arginine 92
Artery 351
Artery, renal 203
Ascorbic acid 435
AT_1-antagonist 167
AT_2-antagonist 167
ATDC5 278
Atherosclerosis 423
ATP 41, 376
ATP-sensitive K^+ channel 29
Atypical β-adrenoceptor 35

Basic cell function 2
Bepridil (1-*N*-benzylanilino-2-pyrodinino-3-isobutoxypropane) 370
Biomembrane peroxidation 227
Blood pressure 197, 313
Blood-brain barrier 271
Bronchial hyperresponsiveness 250
Brown-Norway rat 250

Ca^{2+} antagonist 260
Ca^{2+} channel 260
Ca^{2+} channel, receptor operative 47
Ca^{2+} channel, T-type 339
Ca^{2+} channel blocker 331
Ca^{2+}-dependent Cl^- channel 351
Ca^{2+}-dependent K^+ channel 382
Na^+/Ca^{2+} exchange current 370
Ca^{2+} transient 75
Caffeine 382
Calcium, cytosolic free 98
Camellia sinensis 358
Candesartan cilexetil 416
Carbachol 291
Cardiac myocyte 370
Cardiovascular action 331
Catalase 29
Catecholamine 20, 306
Cation channel, nonselective 291
Cedar pollen 409
Cell differentiation 117
Cell population 214
Cerebral blood flow 271
Cerebral ischemia 271
Channel blocker 260
Chemical mediator 453
Chephaloridine 54
Choline acetyltransferase 11
Chondroitin sulfate 155
Chondroprotection 101
Circadian rhythm 197
Cisplatin 70
Cl^- channel, Ca^{2+}-dependent 351
Cl^--dependent contraction 351
Cl^--dependent depolarization 351
Clonidine 167
Colitis 155
Compound 48/80 443
Concanavalin A 95
Conformationally restricted analog 207
Convulsion 92
Coumarin 95
Crude drug 399
Cyclic AMP 54, 139, 391
Cyclooxygenase-2 175
Cyclopropane 207
Cyclosporine 306
Cynomolgus monkey 282
Cytochrome P450 3A 399
Cytomolecule acetylcholine 2
Cytosolic free calcium 98

Datura stramonium agglutinin 443
Delayed rectifier 124
Dextran sulfate 155
Diabetes 322, 435
Diabetes mellitus, non-insulin-dependent 416
Diabetic neuropathy, painful 335
Diacerein 101
Dihydropyridine 260
Duodenum, guinea pig 35

Elevated plus-maze 189
Emesis 70
Endochondral osteogenesis 278
Endothelial cell 147, 234, 271
Endothelin-1 147
Endothelium 24
Endothelium-derived hyperpolarizing factor 203
Enzyme inhibitor 322
ER-27191 (4-[4,5,7,8,9,10-hexahydro-7,7,10,10-tetramethyl-1-(3-pyridylmethyl)anthra[1,2-*b*]pyrrol-3-yl]benzoic acid) 60
ER-35795 ((2*E*,4*E*,6*E*)-7-[1-(1-methylethyl)-8-chloro-1,2,3,4-tetrahydroquinolin-6-yl]-6-fluoro-3-methyl-2,4,6-nonatrienoic acid) 60

Fibrinogen 114
Fluvastatin 147
FR188582 (3-chloro-5-[4-(methylsulfonyl)phenyl]-1-phenyl-1*H*-pyrazole) 175
Free radical 54
Furanocoumarin 399

D(+)Galactose-specific lectin 443
Gastric lesion 175
Gastric motility 358
Gastric mucosal lesion 133
Gastric smooth muscle 291
Gastric surface mucous cell 117
Gentamicin 391
Arg-gingipain 84
Lys-gingipain 84
Gingivitis 84
Glibenclamide 29
Glomeruli 139
Glutathione, reduced 358, 435
GSM06 117

Na^+/H^+ exchanger 271
Harmaline 299
Harmalol 299
Harmine 299
Heart rate 197
Hemodynamics 183, 241
Hemorrhage 109
Hepatocyte, isolated 227

Hindquarter compensator 109
Histamine 409
Histamine *N*-methyltransferase 105
Histamine release 443
HL60 differentiation 60
5-HT_3 receptor 70
5-HT_4 receptor 70
Human 2
Human placenta 322
Hydrogen peroxide 29
3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor 147
Hypercholesterolemia 203, 423
Hypertension 306
Hypertension, L-NAME-induced 114
Hypertension, portal 183
Hypotension 313

IgE 409
Imidazoline receptor 167
Immobility time 327
Inhibition 399
Inositol 1,4,5-trisphosphate 47
Interleukin-2 16
Isolated hepatocyte 227
Isoproterenol 75

Jurkat cell 16

K^+ channel 124
K^+ channel, ATP-sensitive 29
K^+ channel, Ca^{2+}-dependent 382

L-arginine 92
L-NAME 92, 114
L-NAME-induced hypertension 114
Lectin, D(+)galactose-specific 443
Leupeptin 84
Lidocaine 92
Lipopolysacharride 241
Liver 95
Localization 105
Losartan 167, 365
Lung injury 161
Lymphocyte 11
Lys-gingipain 84
Lysosome 227

Maitotoxin 98
Malignant stroke-prone spontaneously hypertensive rats (M-SHRSP) 197
Mast cell 250, 443
Menatetrenone (vitamin K_2) 335
Mesenteric artery, rat 41
9-Methyl-7-bromoeudistomin D 382
Mibefradil 339
Milnacipran 207
mRNA 105
Muscarinic M_2 antagonist 313
Muscarinic receptor 11, 16
Myocardial ischemia-reperfusion injury 435

Na^+/Ca^{2+} exchange current 370
Na^+/H^+ exchanger 271
Nasal blockage 409
Nasal lavage fluid 453
Neocortical neuron, rat 124
Nephropathy 416
Nephrotoxicity 54
Neuroimmune interaction 16
Neuropathy, painful diabetic 335
Neurotransmitter 20
Neurotrophic factor 20
Nicotinic receptor 11
Ninjin-yoei-to 227
Nitric oxide 133, 147, 234, 299, 358
Nitric oxide synthase 241, 365
Nitro-L-arginine-methyl ester (L-NAME) 92, 114
Nitro-L-arginine-methyl ester-induced hypertension 114
Nitrooxy alkyl apovincaminate 124
NMDA receptor 207
Non-insulin-dependent diabetes mellitus 416
Non-neuronal cholinergic system 2, 24
Nonselective cation channel 291
Noradrenaline release 41

Olopatadine 453
Open channel 260
κ-Opioid agonist 282
κ-Opioid receptor subtype 282
Osteogenesis, endochondral 278
Oxidative stress 227

P2Y receptor 376
Painful diabetic neuropathy 335
Partial agonist 35
Permeabilized fiber 75
(1*S*,2*R*)-1-Phenyl-2-[(*S*)-1-aminopropyl]-*N*,*N*-diethylcyclopropanecarboxamide (PPDC) 207
Phorbol myristate acetate 54
Phosphate 278
(±)-Pindolol 35
Placenta, human 322
Plant 2
Plus-maze, elevated 189
Porphyromonas gingivalis 84
Portal hypertension 183
Pramanicin 234
Prejunctional inhibitory purinoceptor 41
Prostaglandin 133
Prostaglandin E_2 139
Prostaglandin E_2 formation 175
Protein, aggregated 139
Protein kinase A 75, 139
Protein kinase C βII 214
Pulmonary edema 161
Purinoceptor, P2Y 376
Purinoceptor, prejunctional inhibitory 41

R-755 (*N*-(2,6-diethylphenyl)-*N'*-[3-(2-methylphenyl)-6,7-dihydro-5*H*-cyclopenta[*f*][*l*]benzothiophen-2-yl]urea) 423
Radioactive microsphere method 183
Renal artery 203
Renin-angiotensin system 416
Repeated cold stress 189
Retinoic acid receptor 60
Retinoid X receptor 60
Rhein 101
mRNA 105

Sanguinarine 47
SART stress 189
Signal transduction 24
Simian virus 40, temperature-sensitive 117
Single channel 291
Smooth muscle 351
Smooth muscle, gastric 291
Smooth muscle, urinary bladder 382
Smooth muscle, vascular 234
Sodium transport 161
Specific alternation of rhythm in temperature stress 189
Spontaneous transient outward current 382
Spontaneously hypertensive rat 109, 365
Steroidogenesis 376
Stress 189, 313
Stroke 197
Stroke-prone spontaneously hypertensive rats, malignant 197
Substance P 443
Suncus murinus 70
Synaptosome 98
Synephrine 183
Synoviocyte 214

T-type calcium channel 339
Tail suspension test 327
Tea leaf 322
Temperature-sensitive simian virus 40 large T-antigen 117
α-Tocopherol 435
Traditional prescription 399
Transcription factor 306
Transgenic mouse 117
TRK-820 ((−)-17-cyclopropylmethyl-3,14b-dihydroxy-4,5a-epoxy-6b-[*N*-methyl-*trans*-3-(3-furyl)acrylamide] morphinan hydrochloride) 282
Tumor necrosis factor-α 241
Tyrosine hydroxylase 306

Ulcerogen 358
Urinary concentration defect 391

VA-045((+)-eburunamenine-14-carboxylic acid(2-nitroxy-ethyl ester)) 124
Vascular smooth muscle 234
Vasorelaxant 299
Vasorelaxation 47
Vitamin K_2 (menatetrenone) 335

Whole-cell clamp 370
Ws/Ws rat 250